Immunovant Yönetim

Yönetim kriter kontrolleri 2/4

Immunovant CEO'su Pete Salzmann, Dec2019 tarihinde atandı, in görev süresi 4.92 yıldır. in toplam yıllık tazminatı $ 8.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.2% maaş ve 91.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.3% ine doğrudan sahiptir ve bu hisseler $ 11.81M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 4.9 yıldır.

Anahtar bilgiler

Pete Salzmann

İcra Kurulu Başkanı

US$8.6m

Toplam tazminat

CEO maaş yüzdesi8.2%
CEO görev süresi4.9yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi3.1yrs
Yönetim Kurulu ortalama görev süresi4.9yrs

Son yönetim güncellemeleri

Recent updates

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Jul 18
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12
Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30
Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

CEO Tazminat Analizi

Pete Salzmann'un ücretlendirmesi Immunovant'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$323m

Jun 30 2024n/an/a

-US$273m

Mar 31 2024US$9mUS$700k

-US$259m

Dec 31 2023n/an/a

-US$243m

Sep 30 2023n/an/a

-US$255m

Jun 30 2023n/an/a

-US$245m

Mar 31 2023US$6mUS$625k

-US$211m

Dec 31 2022n/an/a

-US$199m

Sep 30 2022n/an/a

-US$177m

Jun 30 2022n/an/a

-US$167m

Mar 31 2022US$6mUS$600k

-US$157m

Dec 31 2021n/an/a

-US$138m

Sep 30 2021n/an/a

-US$128m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021US$15mUS$567k

-US$107m

Dec 31 2020n/an/a

-US$100m

Sep 30 2020n/an/a

-US$79m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020US$9mUS$361k

-US$66m

Tazminat ve Piyasa: Pete 'nin toplam tazminatı ($USD 8.55M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.56M ).

Tazminat ve Kazançlar: Pete şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Pete Salzmann (56 yo)

4.9yrs

Görev süresi

US$8,552,430

Tazminat

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Frank Torti
Executive Chairperson of the Board4.9yrsUS$3.69m0.014%
$ 537.6k
Peter Salzmann
CEO & Director4.9yrsUS$8.55m0.30%
$ 11.8m
Jay Stout
Chief Technology Officer1.6yrsUS$4.04mVeri yok
Eva Barnett
Chief Financial Officer3.1yrsUS$2.07m0.091%
$ 3.6m
Melanie Gloria
Chief Operating Officerno dataVeri yokVeri yok
Mark Levine
Chief Legal Officer & Corporate Secretary2.8yrsVeri yok0.076%
$ 3.0m
Lauren Schrier
Vice President of Marketing4.8yrsVeri yokVeri yok
Christine Blodgett
Senior Vice President of Human Resourcesno dataVeri yokVeri yok
William Macias
Chief Medical Officer3.4yrsUS$1.92m0.13%
$ 5.3m
Andy Deig
Senior Vice President of Strategic Financeno dataVeri yokVeri yok
Michael Geffner
Chief Medical Officerless than a yearVeri yok0.016%
$ 638.2k
Julie Kirschling
Senior Vice President of Program & Alliance Managementno dataVeri yokVeri yok

3.1yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: IMVT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Frank Torti
Executive Chairperson of the Board4.9yrsUS$3.69m0.014%
$ 537.6k
Peter Salzmann
CEO & Director4.9yrsUS$8.55m0.30%
$ 11.8m
George Migausky
Independent Director4.9yrsUS$291.32k0.027%
$ 1.0m
Andrew Fromkin
Director5.1yrsUS$445.00k0.012%
$ 479.6k
Atul Pande
Independent Director5.1yrsUS$287.62k0.022%
$ 869.3k
Douglas Hughes
Independent Director4.9yrsUS$436.30k0.012%
$ 490.3k
Eric Venker
Director4.8yrsUS$55.00kVeri yok

4.9yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMVT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).